Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ADC Therapeutics, SOPHiA GENETICS Partner for Biomarker Discovery | Contract Pharma

What are you searching for?

Sign in
Breaking News

ADC Therapeutics, SOPHiA GENETICS Partner for Biomarker Discovery

Pivotal Phase II trial to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in DLBCL

By: Cassandra Gervolino

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently evaluating ADCT-402 in a Phase II trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
 
SOPHiA technology will match detected genomic markers with clinical response to ADCT-402. The analytical power of SOPHiA will be leveraged for the detection of cancer mutations and is key for this new development phase.
 
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402,” stated Patrick van Berkel, Senior Vice President of Research and Development at ADC Therapeutics. “We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward to the results of this research enabled by SOPHiA’s unique platform.”
 
“We are pleased to partner with ADC Therapeutics, a leader in antibody drug conjugate development, to provide advanced biomarker analysis and turn the results into actionable insights that can improve clinical outcomes for patients and pave the way towards a new era in drug development,” said Esteban Czwan, Senior Vice President BioPharma at SOPHiA GENETICS.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics